Patients with type 2 diabetes (T2D) who have psoriasis showed an increased risk for renal disease, including diabetic neuropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and ...

Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most participants with scalp psoriasis treated with icotrokinra achieved the study’s primary ...

Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents due to an ability to regulate inflammatory signaling pathways.

BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by head-to-head studies showing it was more effective at treating moderate-to-severe psoriasis than ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

Treatment with guselkumab in patients with plaque psoriasis was associated with improvements in 3 biomarkers, yet greater improvements were seen with adalimumab and similar improvements were seen with ...

Credit: surachet virunsap / Shutterstock. Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, which evaluated icotrokinra, an oral peptide, in treating plaque ...

DLQI, Dermatology Life Quality Index NPF-PS, National Psoriasis Foundation Psoriasis Score PASI, Psoriasis Area and Severity Index PGA, physician global assessment The measurement of psoriasis disease ...

This finding is exciting because there is already a drug on the market that does this for psoriasis, which could help us move more quickly toward testing it for type 1 diabetes,” Carmella Evans-Molina ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Tidjane Thiam’s campaign has been halted because presidential candidates are not allowed to hold dual citizenship.